Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children
Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotyp...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2015/591580 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832558185473376256 |
|---|---|
| author | Susanna Esposito Nicola Principi |
| author_facet | Susanna Esposito Nicola Principi |
| author_sort | Susanna Esposito |
| collection | DOAJ |
| description | Applications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies. |
| format | Article |
| id | doaj-art-7a3c1e3d220849c7bb65002f39827452 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-7a3c1e3d220849c7bb65002f398274522025-02-03T01:32:59ZengWileyJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/591580591580Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in ChildrenSusanna Esposito0Nicola Principi1Pediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, ItalyPediatric Highly Intensive Care Unit, Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Commenda 9, 20122 Milan, ItalyApplications of the heptavalent pneumococcal conjugate vaccine (PCV7) in the pediatric immunization schedule have dramatically reduced the incidence of pneumococcal diseases in both vaccinated children and unvaccinated individuals of all ages. However, increased infections caused by non-PCV7 serotypes have been reported by several groups. To overcome this problem, new vaccines covering more serotypes including the emerging serotypes have been developed. The 13-valent pneumococcal conjugate vaccine (PCV13) currently covers the 7 PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional serotypes 1, 3, 5, 6A, 7F, and 19A. After the first year of PCV13 applications in the immunization schedule in young children, global evaluation studies demonstrated that PCV13 provided a wider coverage and more effective prevention than PCV7 against invasive pneumococcal diseases (IPDs), mucosal pneumococcal diseases, and pneumococcal carriage. We reviewed the effects of PCV13 in the control of pneumococcal diseases in children based on previous studies.http://dx.doi.org/10.1155/2015/591580 |
| spellingShingle | Susanna Esposito Nicola Principi Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children Journal of Immunology Research |
| title | Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children |
| title_full | Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children |
| title_fullStr | Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children |
| title_full_unstemmed | Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children |
| title_short | Impacts of the 13-Valent Pneumococcal Conjugate Vaccine in Children |
| title_sort | impacts of the 13 valent pneumococcal conjugate vaccine in children |
| url | http://dx.doi.org/10.1155/2015/591580 |
| work_keys_str_mv | AT susannaesposito impactsofthe13valentpneumococcalconjugatevaccineinchildren AT nicolaprincipi impactsofthe13valentpneumococcalconjugatevaccineinchildren |